News & Events
News / press releases
€ 38.7 Mio. German government funding for the clinical development of a Corona medication
CORAT has been awarded additional funding
CORAT Therapeutics GmbH announces partnership with Dermapharm Holding SE
CORAT Therapeutics GmbH announces partnership with Dermapharm Holding SE
CORAT antibody COR-101 binds and inhibits all B.1.617 SARS-CoV-2 variants, including the fast proliferating “delta” variant
CORAT antibody COR-101 recognizes the current “Indian” mutant B.1.617
CORAT Therapeutics secures additional funding for Phase II clinical evaluation of its COVID-19 treatment
CORAT Therapeutics secures additional funding
events / conferences
events 2021
link
BIO Europe 2021
October 25 – 28, 2021 | Virtual
PEGS Boston 2021
June 10 – 18, 2021 | Virtual
Biologics Europe 2021
April 25 – 28, 2021 | Virtual